z-bio 2025-07-03 2382

　　Artery Network learned at the first time that recently, Suzhou Xiaolu Biotechnology Co., Ltd. (hereinafter referred to as Xiaolu Biotechnology), founded by Professor Liu Yongjun, a world-renowned immunologist, in early 2025, recently completed a angel round financing of tens of millions of dollars.This round of financing was led by Yuansheng Venture Capital and Qiji Investment, followed by Yuanhe Holdings, Hillhouse, Su Venture Capital, Boquan, Beijing Life Science Park, Hefei Industrial Investment and other institutions.

　　Xiaolu Bio focuses on the research and development of innovative drugs for autoimmune and inflammatory diseases, and builds a first-class R&D team, independent R&D strategies and a unique antibody technology platform.The company is committed to developing a safe and efficient new generation of drugs. By finding the most basic targets and target combinations from the pathogenic mechanism, it creates a third-generation drug with more effective efficacy and longer efficacy maintenance time, and strives to achieve the world's first and international leading goals.

　　Regarding this round of financing, Professor Liu Yongjun, founder of Xiaolu Bio, expressed: Thank you for your trust and support from all investors!This angel round financing is of great significance to Xiaolu Bio, injecting sufficient start-up funds into the research and development and industrialization of our new generation of self-immunization and inflammatory drugs, and also represents the capital market's high recognition of Xiaolu Bio's focus on the field of self-immunization and innovation development.

　　Chen Jie, founding partner of Yuansheng Venture Capital, said: Professor Liu Yongjun has made great achievements in the field of immunology as the world's top Chinese scientist. He has pointed out the direction for the research and development of immune drugs through a series of pioneering research, and has personally substituted many globally competitive self-immune drugs into the clinical stage in multinational pharmaceutical companies and local biotechnology companies, showing very excellent therapeutic effects.As the leading investor in this round of financing, we are very happy to be a firm partner in Professor Liu Yongjun's entrepreneurial process, and provide comprehensive assistance in company registration, team building, site implementation, etc.The achievements of China's innovative drugs in recent years are obvious to all, and more and more new drug varieties born in the country have been favored by multinational pharmaceutical companies.We believe that under the leadership of Professor Liu, Xiaolu Bio will give birth to a group of high-quality new drugs with extremely international competitiveness, highly innovative and close to clinical needs, bringing breakthrough therapies to patients with immune diseases around the world.

　　About Xiaolu Biology

　　Xiaolu Bio was founded by Professor Liu Yongjun, an internationally renowned immunologist, and was launched in BioBAY, Suzhou Park in early 2025.Relying on Professor Liu Yongjun's outstanding scientific research accumulation and industrial experience, Xiaolu Bio has broken through the intergenerational limitations of autoimmune drugs and focused on disease targets in the field of autoimmune and inflammatory diseases that have major unmet clinical needs to carry out third-generation drug research and development.By analyzing the heterogeneous pathogenesis of autoimmune diseases, a basic innovation system for precision immunotherapy is built to achieve a leap from single-point technological breakthroughs to systematic source innovation.Its iterative R&D strategies based on the nature of the disease will accelerate the launch of drugs with globally competitive breakthrough therapies to provide patients with better solutions.